OpenResearchAlpha

International Journal of Risk & Safety in Medicine · 20 Nov 2026

Bridging the Health Technology Assessment (HTA)–pharmacovigilance gap: The role of AI-supported real-world evidence in safer drug development and use

Eleonora Castellanah-index 6, Maria Rachele Chiappetta

0
Citations
no database records one yet
0
Citations in 2026
so far
6
Leading author's h-index
Eleonora Castellana, in QAI's scholar index
36
References
works it cites, from open citation data

Citations by database

Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.

  • OpenCitations0
  • Crossref0
  • Europe PMC0

Citations per year

The current year is still counting.

  • 2026 so far0

Abstract

Introduction Health Technology Assessment (HTA) and pharmacovigilance are traditionally considered distinct domains within the lifecycle of medicinal products, focusing, respectively, on value assessment for reimbursement and post-marketing safety surveillance. However, the increasing availability of real-world data (RWD) and real-world evidence (RWE) is progressively blurring the boundaries between these disciplines, enabling a more integrated and dynamic evaluation of health technologies. Objective This overview explores the conceptual and methodological intersections between HTA and pharmacovigilance, with particular emphasis on the role of RWE generated from routine clinical practice. Methods, Overview, Results Evidence derived from pharmacovigilance activities, including spontaneous reporting systems, post-authorization safety studies, patient registries, and large healthcare databases, provides critical insights into long-term safety, effectiveness, and treatment utilization patterns that are often not fully captured in pre-marketing clinical trials. These data can meaningfully inform HTA processes by refining benefit–risk assessments, addressing evidence gaps at the time of reimbursement decisions, and supporting lifecycle reassessment of technologies. Furthermore, emerging analytical approaches, including artificial intelligence and advanced pharmacoepidemiological methods, offer new opportunities to enhance the quality, timeliness, and interpretability of RWE for both regulatory and HTA purposes. Despite these advances, significant challenges remain, including data quality, methodological heterogeneity, governance frameworks, and alignment between regulatory and HTA requirements. Conclusions Strengthening the integration of pharmacovigilance-derived evidence into HTA frameworks may support more adaptive, transparent, and value-based decision-making, ultimately improving patient safety and the sustainability of healthcare systems.

What the data shows

  • No database records a citation yet, as is usual for a paper this new.
  • Eleonora Castellana has the highest h-index among the authors (6).

Graph

This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.

Citing paper shares an authorAuthor without a profileSize shows citations, or h-index for authors

Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.

Start with

Authors (2)

Each author's standing in QAI's scholar index: the works their ORCID iD is attached to, and for anyone whose ORCID record names a lab OpenResearch follows, their arXiv preprints matched by name and a shared co-author. Names are as printed on the paper.

ProfileMost-cited paper

Cited by 0 papers

Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.

0 shown
No citing papers for this filter.

References (36)

What it cites, from open citation data, with Crossref's record of each.

Sign in to see 16 more references

A free account opens the rest of the citing papers and references on every paper’s page.